Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Sep 24, 2015 at 9:55 AM EDT

Why Oppenheimer Says Alexion Is a Cheap Buy Now

Oppenheimer maintained its Outperform rating for Alexion Pharmaceuticals with a price target that implies upside of more than 40%.

Lee Jackson | Sep 24, 2015 at 9:45 AM EDT

Merrill Lynch Has 4 Pharma Stocks to Buy Against Political Chatter

One positive from the hammering the pharmaceutical stocks have taken is the Merrill Lynch analysts say investors have been given…

Chris Lange | Sep 24, 2015 at 8:55 AM EDT

Arrowhead Jumps in Anticipation of Analyst Day

Arrowhead Research shares soared in early trading indications Thursday in anticipation of its analyst day.

Chris Lange | Sep 24, 2015 at 8:50 AM EDT

Conatus Pharmaceuticals Soars on Positive Phase 2 Results

Conatus Pharmaceuticals has announced that its exploratory Phase 2 portal hypertension clinical trial of emricasan met its primary endpoints.

Chris Lange | Sep 23, 2015 at 11:45 AM EDT

Why Key Analyst Sees 25% Upside in Intuitive Surgical

Canaccord Genuity reiterated a Buy rating on Intuitive Surgical with a price target that implies upside of 25% from current…

Chris Lange | Sep 23, 2015 at 11:20 AM EDT

Intra-Cellular Sets Price for Secondary Offering

Intra-Cellular Therapies is gearing up for its secondary offering, and in preparation it just set the price.

Chris Lange | Sep 23, 2015 at 11:05 AM EDT

Heron Therapeutics Soars on Positive Phase 2 Results

Heron Therapeutics Inc. (NASDAQ: HRTX) is bucking the trend of a biotechs and pharmas selling off in the wake of…

Chris Lange | Sep 23, 2015 at 10:45 AM EDT

What Signal Genetics Gets With New Master Service Agreement

ThinkstockSignal Genetics Inc. (NASDAQ: SGNL) soared right out of the gate Wednesday morning on word of a new agreement. Basically,…

Chris Lange | Sep 23, 2015 at 9:50 AM EDT

Orexigen Therapeutics Receives $15 Million Milestone Payment

Orexigen Therapeutics has announced receipt of the first of three potential $15 million anniversary milestone payments from Takeda Pharmaceuticals.

Chris Lange | Sep 22, 2015 at 11:55 AM EDT

How Key Analyst Sees PBMs Responding to Hillary’s Tweet

The recent outcry on social media, focusing on drug pricing, is likely to draw attention to the role of pharmacy…

Chris Lange | Sep 22, 2015 at 11:25 AM EDT

Is the Surge in Ampio Sustainable?

Ampio Pharmaceuticals made waves in the market on Tuesday morning and it looked like a day trader’s dream.

Chris Lange | Sep 21, 2015 at 3:08 PM EDT

Why at Least One Analyst Isn’t Chasing Neogen

Neogen reported disappointing fiscal first-quarter financial results before the markets opened on Monday morning.

Jon C. Ogg | Sep 21, 2015 at 1:20 PM EDT

The Political Tweet That Thrashed the Biotech Sector

On Monday, a simple tweet from presidential candidate Hillary Clinton managed to wreck the biotech sector.

Chris Lange | Sep 21, 2015 at 11:25 AM EDT

Edge Therapeutics Closes in on IPO With Updated Terms

Edge Therapeutics is offering more than 5 million shares in its initial public offering in an expected price range of…

Chris Lange | Sep 21, 2015 at 10:10 AM EDT

NovoCure Gears Up for IPO

NovoCure has made an updated filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).

1 … 243 244 245 246 247 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Why Oppenheimer Says Alexion Is a Cheap Buy Now

Merrill Lynch Has 4 Pharma Stocks to Buy Against Political Chatter

Arrowhead Jumps in Anticipation of Analyst Day

Conatus Pharmaceuticals Soars on Positive Phase 2 Results

Why Key Analyst Sees 25% Upside in Intuitive Surgical

Intra-Cellular Sets Price for Secondary Offering

Heron Therapeutics Soars on Positive Phase 2 Results

What Signal Genetics Gets With New Master Service Agreement

Orexigen Therapeutics Receives $15 Million Milestone Payment

How Key Analyst Sees PBMs Responding to Hillary’s Tweet

Is the Surge in Ampio Sustainable?

Why at Least One Analyst Isn’t Chasing Neogen

The Political Tweet That Thrashed the Biotech Sector

Edge Therapeutics Closes in on IPO With Updated Terms

NovoCure Gears Up for IPO

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Health and Healthcare Articles

All Health and Healthcare Articles

Why Oppenheimer Says Alexion Is a Cheap Buy Now

Merrill Lynch Has 4 Pharma Stocks to Buy Against Political Chatter

Arrowhead Jumps in Anticipation of Analyst Day

Conatus Pharmaceuticals Soars on Positive Phase 2 Results

Why Key Analyst Sees 25% Upside in Intuitive Surgical

Intra-Cellular Sets Price for Secondary Offering

Heron Therapeutics Soars on Positive Phase 2 Results

What Signal Genetics Gets With New Master Service Agreement

Orexigen Therapeutics Receives $15 Million Milestone Payment

How Key Analyst Sees PBMs Responding to Hillary’s Tweet

Is the Surge in Ampio Sustainable?

Why at Least One Analyst Isn’t Chasing Neogen

The Political Tweet That Thrashed the Biotech Sector

Edge Therapeutics Closes in on IPO With Updated Terms

NovoCure Gears Up for IPO

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how